Skip to main content

Cediranib falls short in phase III recurrent glioblastoma study: Commentary

Publication ,  Journal Article
Friedman, HS
Published in: Oncology Report
January 1, 2011

Duke Scholars

Published In

Oncology Report

EISSN

1548-5323

ISSN

1548-5323

Publication Date

January 1, 2011

Issue

JANUARY

Start / End Page

11

Related Subject Headings

  • Oncology & Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Friedman, H. S. (2011). Cediranib falls short in phase III recurrent glioblastoma study: Commentary. Oncology Report, (JANUARY), 11.
Friedman, H. S. “Cediranib falls short in phase III recurrent glioblastoma study: Commentary.” Oncology Report, no. JANUARY (January 1, 2011): 11.
Friedman HS. Cediranib falls short in phase III recurrent glioblastoma study: Commentary. Oncology Report. 2011 Jan 1;(JANUARY):11.
Friedman, H. S. “Cediranib falls short in phase III recurrent glioblastoma study: Commentary.” Oncology Report, no. JANUARY, Jan. 2011, p. 11.
Friedman HS. Cediranib falls short in phase III recurrent glioblastoma study: Commentary. Oncology Report. 2011 Jan 1;(JANUARY):11.

Published In

Oncology Report

EISSN

1548-5323

ISSN

1548-5323

Publication Date

January 1, 2011

Issue

JANUARY

Start / End Page

11

Related Subject Headings

  • Oncology & Carcinogenesis